Sito Bio(SZ:300583) 合成生物学与绿色生物制造·2025-12-17 07:49Core Viewpoint - SynBioCon reports that the biomanufacturing company, Saito Bio, has announced a change in part of its fundraising investment projects, adjusting the total investment of the original project from 367 million yuan to 229 million yuan, and reallocating 124 million yuan to a new project focused on biosynthetic technology research and industrialization [3]. Group 1: Investment Project Changes - The new investment project, "Biosynthetic Technology Research and Industrialization Project," has a total investment of 237 million yuan, with the implementation led by its wholly-owned subsidiary, Jinweiduo, aiming to establish production lines for 1,000 tons/year of Tartrate Tylosin and 200 tons/year of Phosphate Tylosin [5]. - Tartrate Tylosin and Phosphate Tylosin are commonly used drugs for preventing and treating mycoplasma infections in animals, significantly reducing the incidence of respiratory diseases in livestock, indicating strong market demand [5]. Group 2: Company Background and Strategy - Established in 2010, Saito Bio was the first to utilize genetic engineering and synthetic biology for the large-scale production of steroid drug raw materials, becoming a leading supplier of steroid drug raw materials in China [5]. - In 2019, Saito Bio set a long-term industrial upgrade strategy to create a biomanufacturing enterprise integrating "pharmaceutical intermediates - active pharmaceutical ingredients - formulations," successfully producing five major steroid raw material series using synthetic biology [5]. Group 3: Strategic Collaborations - In 2024, the company formed a strategic partnership with AI pharmaceutical company, InSilico Medicine, to leverage cutting-edge AI technology and optimize key steps in the engineering transformation process for synthetic biology research and innovative drug development [6].